Navigating CKD Management Guidelines

This chapter covers recent updates to the KDGO chronic kidney disease guidelines, emphasizing the importance of risk assessment equations over GFR alone. The discussion highlights the use of Cystatin C as a superior marker for kidney function, especially in specific patient populations, and addresses hypertension management in CKD. Speakers also explore the complexities of treating CKD patients with coexisting conditions like diabetes and heart failure, focusing on the benefits of SGLT2 inhibitors among other treatments.